Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Becton Dickinson
(NY:
BDX
)
193.57
+3.10 (+1.63%)
Official Closing Price
Updated: 7:00 PM EST, Dec 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Becton Dickinson
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
BD Bolsters Portfolio With $4.2B Cash Deal For Edwards Lifesciences' Critical Care Group: Details
↗
June 03, 2024
BD (Becton, Dickinson and Company) will acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition enhances BD's portfolio with advanced AI-enabled monitoring...
Via
Benzinga
Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal
↗
June 03, 2024
Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinson's plan to buy a key division for $4.2 billion.
Via
Investor's Business Daily
Trade Winds Turning: 3 Stocks Poised to Gain from Biden’s China Tariffs
↗
May 21, 2024
Here are three potential stocks to buy that could benefit from China tariffs amidst the turning trade winds.
Via
InvestorPlace
Topics
World Trade
Biden's New Tariffs On Chinese Imports Are A 'Clear Giveaway' To These Two Tesla Rivals, Jim Cramer Says: 'I Like This Policy'
↗
May 15, 2024
Jim Cramer has highlighted the potential benefits for U.S. automakers, particularly Ford and General Motors, following the Biden administration's decision to impose substantial tariffs on Chinese...
Via
Benzinga
Topics
World Trade
Looking Into Becton Dickinson's Recent Short Interest
↗
April 29, 2024
Via
Benzinga
Peering Into Becton Dickinson's Recent Short Interest
↗
March 29, 2024
Via
Benzinga
Peering Into Becton Dickinson's Recent Short Interest
↗
February 21, 2024
Via
Benzinga
Becton Dickinson Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
↗
February 05, 2024
Via
Benzinga
MarketBeat Week in Review – 4/29 - 5/3
May 04, 2024
Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024
Via
MarketBeat
Topics
Economy
Stocks
10 Health Care Stocks Whale Activity In Today's Session
↗
May 03, 2024
Via
Benzinga
Becton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook
↗
May 02, 2024
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX...
Via
Benzinga
BDX Stock Earnings: Becton, Dickinson Beats EPS, Beats Revenue for Q2 2024
↗
May 02, 2024
BDX stock results show that Becton, Dickinson beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Earnings Preview For Becton, Dickinson
↗
January 31, 2024
Via
Benzinga
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
April 30, 2024
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook.
Via
MarketBeat
How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?
↗
April 26, 2024
Curious to know how much these dividend aristocrats could grow in the next year? Here's the answer for several well-known shares.
Via
InvestorPlace
Rich Returns at a Discount: 3 Dividend Aristocrats Trading at 52-Week Lows
↗
April 03, 2024
Want quality picks and reliable income at a discount? Check out these Dividend Aristocrats trading at 52-week lows.
Via
InvestorPlace
AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement
↗
April 02, 2024
AngioDynamics resolves decade-long patent litigation with Becton, Dickinson in landmark settlement, streamlining legal expenses and marking a significant milestone for the company.
Via
Benzinga
Topics
Intellectual Property
Should You Buy Solventum (SOLV) Stock After the 3M Spinoff?
↗
April 01, 2024
Although 3M shareholders have reason to dump the Solventum spinoff, SOLV stock could be intriguing at the right price.
Via
InvestorPlace
Jim Cramer Says Don't Sell This Beauty Brand, Believes KKR And Blackstone 'Can Make More Money'
↗
March 26, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer sang the praises of Energy Transfer LP (NYSE: ET), which posted better-than-expected earnings
Via
Benzinga
Becton, Dickinson And Co. Dividend Stock Analysis
↗
March 23, 2024
Becton, Dickinson, and Co. provides a wide range of medical devices and diagnostic products used in hospitals, doctors' offices, research labs, and other settings.
Via
Talk Markets
FDA Probe On China-Made Syringes: Becton Dickinson Boosts US Syringe Output Following Concerns
↗
March 21, 2024
BD boosts U.S. production of medical syringes following FDA concerns over Chinese-made syringes. Learn how BD addresses patient care continuity amid ongoing quality probe.
Via
Benzinga
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
↗
March 16, 2024
Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...
Via
Talk Markets
7 Robotic Surgery Stocks to Buy for the Future of Healthcare
↗
March 13, 2024
Discover seven robotic surgery stocks primed for growth as the industry evolves. Unveil opportunities in a market set to double by 2033.
Via
InvestorPlace
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
↗
March 11, 2024
These are some of the best-performing stocks in what's arguably society's most important industry.
Via
The Motley Fool
3 Stocks to Buy at 52-Week Lows: March 4 Edition
↗
March 04, 2024
Sometimes a gem can get tossed in the trash, which is what you will find with these three stocks to buy at 52-week lows.
Via
InvestorPlace
Get Paid While You Wait: 7 Dividend Aristocrats to Buy Now
↗
February 27, 2024
Worried about an upcoming market correction? These seven Dividend Aristocrats are a safe harbor which offer great income streams.
Via
InvestorPlace
Medical Device Maker Becton Dickinson's Q1 Earnings: Here's Why This Analyst Is Bullish On Long-Term Prospects
↗
February 01, 2024
BD exceeds expectations with Q1 2024 adjusted EPS of $2.68 (vs $2.40 consensus). William Blair maintains a positive outlook, confident in BD's progress towards its 2025.
Via
Benzinga
Earnings Scheduled For February 1, 2024
↗
February 01, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...
Via
Benzinga
Biotech And Medtech Portfolio Notes On A Fed Day
↗
January 31, 2024
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%
Via
Talk Markets
Topics
Economy
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
↗
January 23, 2024
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today